These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34267813)

  • 1. Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness.
    Patel JR; Gallegos KM; Walker RR; Davidson AM; Davenport I; Tilghman SL
    Oncol Lett; 2021 Aug; 22(2):620. PubMed ID: 34267813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
    Patel JR; Banjara B; Ohemeng A; Davidson AM; Boué SM; Burow ME; Tilghman SL
    Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
    Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
    Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
    Carriere PP; Llopis SD; Naiki AC; Nguyen G; Phan T; Nguyen MM; Preyan LC; Yearby L; Pratt J; Burks H; Davenport IR; Nguyen TA; Parker-Lemieux K; Payton-Stewart F; Williams CC; Boué SM; Burow ME; Collins-Burow B; Hilliard A; Davidson AM; Tilghman SL
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010010. PubMed ID: 26703648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.
    Gallegos KM; Patel JR; Llopis SD; Walker RR; Davidson AM; Zhang W; Zhang K; Tilghman SL
    Front Oncol; 2021; 11():540134. PubMed ID: 33718123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
    Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
    Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
    Nair HB; Huffman S; Veerapaneni P; Kirma NB; Binkley P; Perla RP; Evans DB; Tekmal RR
    J Nanosci Nanotechnol; 2011 May; 11(5):3789-99. PubMed ID: 21780370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
    Wang J; Gildea JJ; Yue W
    Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines.
    Gonçalves Ndo N; Colombo J; Lopes JR; Gelaleti GB; Moschetta MG; Sonehara NM; Hellmén E; Zanon Cde F; Oliani SM; Zuccari DA
    PLoS One; 2016; 11(3):e0150407. PubMed ID: 26934679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the stemness potency of
    Yousefnia S; Ghaedi K; Seyed Forootan F; Nasr Esfahani MH
    Tumour Biol; 2019 Aug; 41(8):1010428319869101. PubMed ID: 31423948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
    Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
    BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
    Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
    Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.
    Grimshaw MJ; Cooper L; Papazisis K; Coleman JA; Bohnenkamp HR; Chiapero-Stanke L; Taylor-Papadimitriou J; Burchell JM
    Breast Cancer Res; 2008; 10(3):R52. PubMed ID: 18541018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors.
    Wang R; Lv Q; Meng W; Tan Q; Zhang S; Mo X; Yang X
    J Thorac Dis; 2014 Jun; 6(6):829-37. PubMed ID: 24977009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
    Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
    BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.